Lilly Articles
Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis
2 April 2013
Lilly CEO tells German audience there is a need for shift in thinking on health reform; says German uptake of new drugs slow
25 March 2010
UK’s NICE sets national standard for neuropathic pain drug treatments in non-specialist NHS settings; guidance on angina
25 March 2010
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
One cheer for Pfizer’s Fablyn
26 February 2010
US FDA warns Lilly on insulin API manufacturing violations and Roche and Abbott over HIV combo drug concerns
24 February 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
Neuropathic pain - brighter future for pipeline drugs with market to double in value to $5.2 billion
17 February 2010
UK Appeal Court invalidates HGS/GlaxoSmithKline lupus drug patent; Simcere cleared to manufacture and sell zanamivir in China
11 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Cost to treat pain varies significantly by chronic pain condition, AAPM meeting hears
5 February 2010
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
Biogen Idec receives “notice of intention” from Icahn to nominate three more directors
29 January 2010
FDA approves Novo Nordisk’s new type 2 diabetes drug Victoza
26 January 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
World fibromyalgia syndrome market to grow at a CAGR of 9.2% for the next seven years, reaching $1.8 billion by 2015, forecasts Global Data
11 January 2010
Pfizer makes another move into generics in deal with Strides Arcolab; enters into discovery accord with Ensemble
7 January 2010
Eli Lilly gets bonus with FDA’s Zyprexa Relprew approval
4 January 2010
Lilly in deal with Kowa to co-promote newly-approved statin Livalo in USA and commercialization rights for Latin America
24 December 2009
Lilly gains global rights to Incyte's novel JAK1/JAK2 inhibitor for $90 million upfront and up to $665 million more; deal with PDL
22 December 2009
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
Silence Thera to merge with Intradigm to create leading RNAi company
17 December 2009
Data uncertainties mean NICE unable to recommend pemetrexed for NSCLC maintenance treatment
17 December 2009
Eli Lilly outlines innovation strategy, sets 2010 financial guidance, but disappoints Wall Street
11 December 2009
Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn
8 December 2009
Bristol-Myers Squibb and Pfizer to file apixaban In Europe; J&J unit submits palmitate for schizophrenia
7 December 2009
Regulatory approval briefs: Betaferon in China; new use for Lilly’s Cymbalta in USA; update on telavancin
1 December 2009
Merck KGaA's Erbitux boosts colorectal cancer survival rate
27 November 2009
Clavis Pharma and Clovis Oncology sign $380 million deal for anti-cancer agent CP-4126
26 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Merck KGaA gets second CHMP rejection for Erbitux in Advanced Non-Small Cell Lung Cancer
20 November 2009
Bristol-Myers Squibb decides to split off Mead Johnson nutritional unit to concentrate on biopharma
17 November 2009
PhRMA proposes FDA-approved logo for link to patient info on-line
16 November 2009
Pharmerging markets: China - Leaders, Followers and Latecomers
13 November 2009
Confederation of Indian Industry and US India Business Council enter health care partnership
6 November 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
US FDA revises Byetta label to reflect possible kidney problems
3 November 2009
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots
28 October 2009
Atypical antipsychotics cause significant weight gain in children and young adults, JAMA study reports
28 October 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Flexion Therapeutics raises $33 million in Series A financing
20 October 2009
Merck KGaA hit by disappointing Erbitux results from COIN study
24 September 2009
Lilly names David Ricks as new US affiliate leader; Eric Baclet to head up China business
23 September 2009
Servier’s Valdoxan superior to Prozac for severe depression in adults
19 September 2009
Eli Lilly names new business leaders
15 September 2009
Sanofi-Aventis and Regeneron discontinue one Ph III study of aflibercept
14 September 2009
Public Citizen’s HRG slams Pfizer’s $2.3 billion settlement as not enough to deter bad behaviour by Pharma
9 September 2009
Lilly plans to appeal over Gemzar's intellectual property
7 September 2009
J&J decision to halt risperidone inj a setback for Alkermes’ pipeline, say analysts
1 September 2009
Bristol-Myers Squibb says USPTO to review Plavix patent
20 August 2009
Lilly drops arzoxifene filing after mixed Ph III results
19 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
'Eli Lilly-Children International' launches Teen Campaign to reduce TB cases in India
14 August 2009
Amgen scores with cancer drug, says Zacks analysts
10 August 2009
Aileron closes $40M financing
9 June 2009
Lilly compound shows insulinotropic effect
8 June 2009
Lilly resubmits Cymbalta sNDA for
5 June 2009
Japan stock market week to June 1, 2009
3 June 2009
UK's NICE OKs Merck KGaA's Erbitux for mCRC
2 June 2009
Novartis, Novo, Lilly, BI breach ABPI Code
1 June 2009
Tracleer plus tadalafil boosts 6MWD
28 May 2009
Japan: no added use for Nexavar, Alimta
27 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
Exenatide once weekly NDA submitted to FDA
6 May 2009
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
